Search Results - "Spriano F"

301 (PB081) - The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds.

Authors: Spriano, F. Arribas, A.J. Tarantelli, C. et al.

Source: European Journal of Cancer. 2022 Supplement 1, Vol. 174, pS107-S107. 1p.

36 Poster Discussion - Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models.

Authors: Spriano, F. Barreca, M. Miguel-Gordo, M. et al.

Source: European Journal of Cancer. 2020 Supplement 2, Vol. 138, pS17-S17. 1p.

97 - PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL).

Authors: Arribas, A. Rinaldi, A. Spriano, F. et al.

Source: European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS39-S39. 1p.

99 - The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models.

Authors: Gaudio, E. Tarantelli, C. Spriano, F. et al.

Source: European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS39-S40. 1p.

251 - Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes.

Authors: Ricci, F. Brunelli, L. Spriano, F. et al.

Source: European Journal of Cancer. Jul2016 Supplement 1, Vol. 61, pS46-S47. 1p.

304 (PB084) - Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors.

Authors: Arribas, A. Vultaggio, S. Andronache, A. et al.

Source: European Journal of Cancer. 2022 Supplement 1, Vol. 174, pS108-S108. 1p.

842P Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models.

Authors: Arribas, A.J. Napoli, S. Cascione, L. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS779-S779. 1p.

149 Poster - Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma.

Authors: Arribas, A. Napoli, S. Cascione, L. et al.

Source: European Journal of Cancer. 2020 Supplement 2, Vol. 138, pS40-S40. 1p.

96 - The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas.

Authors: Tarantelli, C. Gaudio, E. Hillmann, P. et al.

Source: European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS38-S38. 1p.

Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies.

Authors: Spriano F Arribas AJ Zhang F et al.

Source: EJHaem [EJHaem] 2026 Mar 30; Vol. 7 (2), pp. e70267. Date of Electronic Publication: 2026 Mar 30 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101761942 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-6146 (Electronic) Linking ISSN: 26886146 NLM ISO Abbreviation: EJHaem Subsets: PubMed not MEDLINE

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Authors: Arribas AJ Cannas E Sartori G et al.

Source: Blood [Blood] 2026 May 29. Date of Electronic Publication: 2026 May 29.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.

Authors: Spriano F Cascione L Tarantelli C et al.

Source: Cancer medicine [Cancer Med] 2026 May; Vol. 15 (5), pp. e71935.

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Development of C646-Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300.

Authors: Fiorentino F Spriano F Tomaselli D et al.

Source: ChemMedChem [ChemMedChem] 2025 Jun 17; Vol. 20 (12), pp. e202400792. Date of Electronic Publication: 2025 Apr 11.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101259013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1860-7187 (Electronic) Linking ISSN: 18607179 NLM ISO Abbreviation: ChemMedChem Subsets: MEDLINE

A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.

Authors: Zadro A Arribas A Colombo MV et al.

Source: British journal of haematology [Br J Haematol] 2026 Feb; Vol. 208 (2), pp. 716-721. Date of Electronic Publication: 2025 Dec 08.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.

Authors: Spriano F Tarantelli C Cascione L et al.

Source: British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 1873-1882. Date of Electronic Publication: 2024 Jul 30.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma.

Authors: Jennings LK Spriano F Reddy MM et al.

Source: Chembiochem : a European journal of chemical biology [Chembiochem] 2025 Oct 03; Vol. 26 (19), pp. e202500500. Date of Electronic Publication: 2025 Sep 11.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-VCH Verlag Country of Publication: Germany NLM ID: 100937360 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-7633 (Electronic) Linking ISSN: 14394227 NLM ISO Abbreviation: Chembiochem Subsets: MEDLINE

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.

Authors: Sartori G Tarantelli C Spriano F et al.

Source: British journal of haematology [Br J Haematol] 2024 Jan; Vol. 204 (1), pp. 191-205. Date of Electronic Publication: 2023 Nov 27.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas.

Authors: Tarantelli C Spriano F Civanelli E et al.

Source: Cancers [Cancers (Basel)] 2025 Jun 18; Vol. 17 (12). Date of Electronic Publication: 2025 Jun 18.

Publication Type: Journal Article

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Authors: Arribas AJ Guidetti F Cannas E et al.

Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 May 10. Date of Electronic Publication: 2025 May 10.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP.

Authors: Arribas, A. Napoli, S. Cascione, L. et al.

Source: Hematological oncology Jun2023 Supplement S2; Vol. 41.

Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232